GrpE-like 1-engineered synovial mesenchymal stromal cell exosomes: Mechanistic and translational priorities in osteoarthritis

Table 1 Condensed evidence-and-gap map for the GrpE-like 1-phosphatase and tensin homolog-induced kinase 1-mitophagy axis in osteoarthritis

Evidence layer	Source/model	Key readouts	Bottom-line message	Strength	Key gap/next step
In silico nomination	Public OA cartilage transcriptomes (GSE169077; GSE114007)	DEG/prioritization; pathway enrichment; immune deconvolution	GRPEL1 emerges as a mitochondria/MQC-associated candidate with disease/immune association tags	Associative	Validate across additional cohorts/platforms; control for cell-composition confounding
Human association	Human OA vs controls (biofluids/tissue) + clinical indices	GRPEL1 level vs CRP/IL-6/TNF-α; KL grade	Lower GRPEL1 associates with higher inflammatory burden and worse radiographic severity	Correlative (cross-sectional)	Independent validation cohort; analytic validation of protein assays (IHC/ELISA) and clinically usable thresholds
Product definition	SMSC-Exos ± GRPEL1 engineering	EV identity markers; particle metrics; GRPEL1 enrichment	Engineering plausibly alters cargo and strengthens biological activity	Enabling (not MoA proof)	Quantify GRPEL1 per dose/particle; define release specs and batch comparability
In vitro efficacy	IL-1β-challenged chondrocytes	Proliferation/migration; ECM markers; oxidative injury; ΔΨm	GRPEL1-Exos improve injury phenotypes and ECM balance	Functional	Distinguish pleiotropy vs mitophagy dependence; add flux-aware mitophagy readouts
Mechanistic anchoring	Co-IP + pathway perturbation	GRPEL1-PINK1 association; PINK1 loss-of-function attenuates benefit	Supports a PINK1-dependent linkage rather than generic anti-inflammatory effects	Causal-supporting	Event-level tags (e.g., pS65-Ub; Parkin recruitment) + mitophagy flux confirmation
In vivo outcome	DMM rat OA; intra-articular dosing	OARSI/ICRS; histology; ECM IHC; mitophagy-associated tissue signals	Structural benefit with cargo dependence is shown preclinically	Strong preclinical coherence	Joint PK/retention; repeated-dose safety; large-animal bridging; PD-to-regimen linkage and patient endotype

OA: Osteoarthritis; DEG: Differentially expressed gene(s); GRPEL1: GrpE-like 1; MQC: Mitochondrial quality control; CRP: C-reactive protein; IL-1β: Interleukin-1 beta; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-alpha; KL: Kellgren-Lawrence; IHC: Immunohistochemistry; ELISA: Enzyme-linked immunosorbent assay; SMSC-Exos: Synovial mesenchymal stem cell-derived exosomes; EV: Extracellular vesicle(s); MoA: Mechanism of action; ECM: Extracellular matrix; ΔΨm: Mitochondrial membrane potential; Exos: Exosomes; Co-IP: Co-immunoprecipitation; PINK1: Phosphatase and tensin homolog-induced kinase 1; pS65-Ub: Phospho-Ser65 ubiquitin; DMM: Destabilization of the medial meniscus; OARSI: Osteoarthritis Research Society International; ICRS: International Cartilage Repair Society; PK: Pharmacokinetics; PD: Pharmacodynamics.

Table 2 Mechanism-to-translation checklist for GrpE-like 1-exosomes

Domain	Minimal assay set (examples)	What counts as “engagement/Go”	Pitfall if omitted
Target engagement (event): PINK1 on mitochondria	Mito/cyto fractionation + WB; IF colocalization with TOM20/VDAC (time-course)	↑Mitochondria-localized PINK1 with temporal precedence	Total PINK1↑ ≠ pathway activation
Target engagement (event): PS65-Ub/Parkin recruitment	pS65-Ub WB/IF; Parkin translocation/ubiquitination assays	Event tags increase on mitochondria and are PINK1-dependent	Marker noise/non-specific stress responses
Target engagement (flux): Mitophagy completion	Lysosomal end-blockade designs ± mito-QC/mt-Keima reporters	Demonstrates increased mito → lysosome delivery/turnover (not stalled autophagy)	Static LC3/p62 shifts misread as “more mitophagy”
Functional PD bridging	ΔΨm, mtROS, OCR/ATP reserve; oxidative injury panels	Functional rescue tracks with event + flux engagement	Pleiotropic effects confound MoA claims
Disease PD (cartilage biology)	COL2/ACAN vs MMP13/ADAMTS5; histology/OARSI	Downstream benefit interpreted only after engagement is shown	“Downstream-only” ≠ mechanism proof
CMC identity & purity	EV identity markers + sizing/quantitation; impurities (ApoA1/albumin), endotoxin/sterility	Lot-to-lot consistency; contaminants below thresholds; injectable safety specs met	Non-comparability; false efficacy/safety signals
Cargo quantification (GRPEL1)	GRPEL1 amount per dose/particle; stability (storage/shipping)	Defined cargo attribute linked to potency	“Engineered” becomes non-reproducible
Potency assay for release	Mechanism-linked assay (event + flux preferred) in recipient chondrocytes	Potency correlates with GRPEL1 Loading and predicts in vivo PD	Release testing becomes non-informative
IA PK/retention & BD	Joint residence time; distribution; clearance	Regimen feasible; PD aligns with exposure	Efficacy irreproducible; dosing unrealistic
Safety & immunogenicity	Local synovitis; systemic cytokines; repeat-dose tolerability	Acceptable safety window with repeat IA dosing	Hidden inflammation/off-target risk
Stratification	Inflammation-high/mitochondrial-stress-high endotypes; KL stage	Enrichment improves signal and PD-response mapping	Heterogeneity → “negative trial” risk

“Go” decision requires simultaneous satisfaction of: (1) Chemistry, manufacturing, and controls-defined critical quality attributes; (2) Mechanism-linked potency anchored to event + flux mitophagy pharmacodynamics; and (3) Intra-articular pharmacokinetics/pharmacodynamics-supported regimen feasibility. PINK1: Phosphatase and tensin homolog-induced kinase 1; WB: Western blot; IF: Immunofluorescence; TOM20: Translocase of outer mitochondrial membrane 20; VDAC: Voltage-dependent anion channel; pS65-Ub: Phospho-Ser65 ubiquitin; mito-QC: Mitochondrial quality control reporter; LC3: Microtubule-associated protein 1A/1B-light chain 3; p62: Sequestosome 1; ΔΨm: Mitochondrial membrane potential; mtROS: Mitochondrial reactive oxygen species; OCR: Oxygen consumption rate; ATP: Adenosine triphosphate; MoA: Mechanism of action; PD: Pharmacodynamics; COL2: Type II collagen (collagen type II alpha 1 chain); ACAN: Aggrecan; MMP13: Matrix metalloproteinase 13; ADAMTS5: A disintegrin and metalloproteinase with thrombospondin motifs 5; OARSI: Osteoarthritis Research Society International; CMC: Chemistry, manufacturing, and controls; EV: Extracellular vesicle(s); ApoA1: Apolipoprotein A1; GRPEL1: GrpE-like 1; IA: Intra-articular; PK: Pharmacokinetics; BD: Biodistribution.